deucrictibant
Sponsor Pharvaris N.V. · listed as PHVS
deucrictibant is a drug asset sponsored by Pharvaris N.V., listed as PHVS. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Jun 2027 (month precision, medium confidence), tied to trial NCT05396105. That trial is in Phase 2/3 and currently enrolling by invitation, studying Hereditary Angioedema. It appears across 4 tracked trials in the CSA sample.
Next catalyst
Trial & sponsor
Trials for deucrictibant in the CSA sample
| Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|
| NCT06669754 | Phase 3 | Active, not recruiting | 2026-08 | Experimental | Pharvaris Netherlands B.V. | Hereditary Angioedema (HAE) |
| NCT05396105 catalyst | Phase 2/3 | Enrolling by invitation | 2027-06 | Experimental | Pharvaris Netherlands B.V. | Hereditary Angioedema; Hereditary Angioedema Type I; Hereditary Angioedema Type II; Heredi… |
| NCT07266805 | Phase 3 | Recruiting | 2027-06 | Experimental | Pharvaris Netherlands B.V. | Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH) |
| NCT06679881 | Phase 3 | Enrolling by invitation | 2028-12 | Experimental | Pharvaris Netherlands B.V. | Hereditary Angioedema (HAE) |
Each trial links to its ClinicalTrials.gov record; primary completion dates are as registered there.
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 → More PHVS catalysts